- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
- KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
More ▼
Key statistics
As of last trade, Kalvista Pharmaceuticals Inc (KALV:NMQ) traded at 10.54, 46.19% above the 52 week low of 7.21 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.50 |
---|---|
High | 10.66 |
Low | 10.26 |
Bid | 10.52 |
Offer | 10.55 |
Previous close | 10.49 |
Average volume | 353.94k |
---|---|
Shares outstanding | 42.19m |
Free float | 41.71m |
P/E (TTM) | -- |
Market cap | 442.56m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 16:24 BST.
More ▼